ALNYLAM PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 13, 2025
ALNY$151.64-3.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 202 and
(In thousands, except per share amounts)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $966,428 | $812,688 |
| Marketable debt securities | 1,719,920 | 1,615,516 |
| Marketable equity securities | 8,156 | 11,178 |
| Accounts receivable, net | 405,308 | 327,787 |
| Inventory | 78,509 | 89,146 |
| Prepaid expenses and other current assets | 116,964 | 126,382 |
| Total current assets | 3,295,285 | 2,982,697 |
| Property, plant and equipment, net | 502,784 | 526,057 |
| Operating lease right-of-use assets | 191,148 | 199,732 |
| Deferred tax assets | 116,863 | 10,101 |
| Restricted investments | 68,593 | 49,391 |
| Other assets | 65,310 | 61,902 |
| Total assets | $4,239,983 | $3,829,880 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $88,415 | $55,519 |
| Accrued expenses | 887,472 | 713,013 |
| Operating lease liabilities | 41,886 | 41,510 |
| Deferred revenue | 55,481 | 102,753 |
| Liability related to the sale of future royalties | 113,018 | 54,991 |
| Total current liabilities | 1,186,272 | 967,786 |
| Operating lease liabilities, net of current portion | 229,541 | 243,101 |
| Deferred revenue, net of current portion | — | 188,175 |
| Convertible debt | 1,024,621 | 1,020,776 |
| Liability related to the sale of future royalties, net of current portion | 1,334,353 | 1,322,248 |
| Other liabilities | 398,108 | 308,438 |
| Total liabilities | 4,172,895 | 4,050,524 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of December 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.01 par value per share, 250,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively; 129,294 shares issued and outstanding as of December 31, 2024; 125,794 shares issued and outstanding as of December 31, 2023 | 1,293 | 1,259 |
| Additional paid-in capital | 7,388,061 | 6,811,063 |
| Accumulated other comprehensive loss | (34,518) | (23,375) |
| Accumulated deficit | (7,287,748) | (7,009,591) |
| Total stockholders’ equity (deficit) | 67,088 | (220,644) |
| Total liabilities and stockholders’ equity (deficit) | $4,239,983 | $3,829,880 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.